#Glenmark#favipiravir grabbed attention for its role in mild cases of #covid
But mild cases dont need much other than supportive treatment
Home quarantine, nutritional supplements in form of vitamin,zinc
Symptomatic treatment for fever,cough,bodyache
Monitor O2 levels,fever
Severe #coronavirus cases develop cytokine storm on a few instances
CRP, PCT, IL-6, ESR, SAA, and serum ferritin are indicators for severity of COVID-19
Inj Methylprednisolone, dexamethasone and inj Tocilizumab are used to suppress the inflammatory response
Inj Tocilizumab developed by Roche, marketed by Cipla in India is being used in severe cases of #covid19 with extreme immune response termed cytokine storm leading to multiorgan failure & death
Inj #tocilizumab slows the cytokine storm by modulating IL-6 @Roche@Cipla_Global
Inj Tocilizumab is marketed under the brand name Acemtra
Cost 60,000 per dose,may require 3-4 injections and short supply are major hindrances
Tab #CORONIL launched #patanjali ,being advocated as a cure. They need to reveal data of patients, age group,mild or severe,comorb's
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Laurus Synthesis Private Limited ,CDMO subsidiary signed multi-year contract with global life science company in Q2 ,entails complete drug development & mfng portfolio niche APIs
Evolving China issues - impact API prices,RM,logistics
#lauruslabs
No's in line
Rev 1411.9 vs 839.1 cr yoy
EBIDTA 450.3 vs 191.8 Cr
EBITDA Margin 31.9% vs 22.9% yoy
PAT 296.9 vs 110.2 Cr yoy EPS 5.53 vs 2.06
Fy21 /20
Rev 4837 vs 2837
PAT 317 vs 38
EPS 18.36 vs 4.79 #Q4updates🐝
Generic API division robust growth 61% YoY
Anti Viral growth of 70% YoY
Generic FDF Rev up 102% YoY
Growth led by higher LMIC mkt vols & increased
vols from US & EU
Custom Synthesis division recorded a strong growth of 35% YoY
Generic API Division
Strong demand 1st line ARV API
Robust order book ,adding more capacity to meet demand
Other APIs (CVS , DM) good growth
Discussion with Generic Partners for CM opportunity
Dedicated block for Non-ARV APIs, expansion of
High Potent capacity at Unit 4
#subex#Q3marketupdates#Q3concall#Q3updates
Concall transcript Q3fy21
Rev 93.9 cr ,Ebidta 20.3 cr & PAT 8.5 cr
9mfy21 Rev 275.9 cr up 6% yoy
Interim dividend of 10%
Moved into new corporate office in Bengaluru
In IoT focus on mftng sector,secured 4 new customers in Q3
ID central (identity analytics solution) launched in Indonesia, 1st customer onboard
NGP platform, next gen platform to revolutionize way telcos operate in OSS & BSS system ,cloud native API based application
Expect more 5g contracts in APAC & ME in coming quarters
Vision to emerge as a leader in digital trust solutions in multi vertical environment
Closed about $28.5mn deals in 9mfy21 ,Q4 to exceed Q3 in deal wins
Tech mahindra partnership around Block chain area
New product offering for Telcos- Augmented Analytics platform
Vols Q3fy21/20
Performance surfactants 36618/34978
Speciality 21620/19295
Total 58238/54273
Revenue HLs
Q3fy21/20 in crs
Performance surfactants 401/387
Speciality 277/242
Total 678/629
PAT 85/48
9mnths fy21 vols
India mkt up 13.3%
Africa & ME Up 6.3%
ROW down -10.1%
9mnth FHs in cr
PS 1292/1187
Speciality 717/759
Total 2009/1946
PAT 223/168
Truly Indian MNC
:Leading mftr of ingredients for home & personal care industry
:preferred supplier for MNC,Regional & local Fmcg
:205+ product grades
: 7 strategic facilities (5 India,1Egypt ,1 US)
: Extensive R&D capacity
: intellectual property- 78 approved,1e applied